Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal Depression and Opioid Use After Cesarean Delivery.

Obstetrics and gynecology·2026
Same author

Cesarean Anesthesia Type and Neonatal Outcomes: Comment.

Anesthesiology·2026
Same author

Pain during Cesarean Delivery with Neuraxial Anesthesia: Have We Made Any Progress?

Anesthesiology·2026
Same author

Responsible use of large language models in manuscript authorship, peer review, and editorial processes: a Delphi consensus among editors-in-chief of anaesthesia and pain medicine journals (RULE-AP).

British journal of anaesthesia·2026
Same author

Childhood sexual abuse and post-cesarean pain.

Pregnancy (Hoboken, N.J.)·2026
Same author

Selective nonreporting of 5-min Apgar scores and its safety assessment of out-of-hospital births: a population-based study of United States' birth data, 2016-2023 a population based study.

Lancet regional health. Americas·2026

Related Experiment Video

Updated: Jul 5, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

[Genetic polymorphisms and opioid therapies].

Ruth Landau1

  • 1Service d'anesthésiologie, Département APSI, Hôpitaux Universitaires de Genève, CH-1211 Genève 14, Suisse, France. ruth.landau@hcuge.ch

Presse Medicale (Paris, France : 1983)
|April 29, 2008
PubMed
Summary

Genetic variations influence how individuals experience pain and respond to opioid medications. Key genes impact opioid metabolism and drug targets, explaining differences in pain relief and side effects.

Area of Science:

  • Pharmacogenetics
  • Neuroscience
  • Genetics

Context:

  • Individual differences in pain perception and opioid response are well-established.
  • Genetic factors are increasingly recognized as crucial in pain management and opioid pharmacogenetics.
  • Studying pain genetics is complex but essential for personalized medicine.

Purpose:

  • To explore the genetic underpinnings of interindividual variability in pain perception.
  • To identify genetic polymorphisms that modulate nociception and opioid antinociception.
  • To investigate the role of specific genes in opioid pharmacokinetics and pharmacodynamics.

Summary:

  • Genetic polymorphisms significantly affect pain signaling and the effectiveness of opioids.
  • Genes involved in opioid metabolism (e.g., cytochrome P450) and neurotransmitter pathways (e.g., catechol-O-methyltransferase) play a role.

Related Experiment Videos

Last Updated: Jul 5, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

  • Variations in drug targets, including the mu-opioid receptor and melanocortin 1-receptor, also influence opioid response.

    • Impact:

    • Understanding these genetic factors can lead to more personalized pain management strategies.
    • This research may improve opioid efficacy and reduce adverse side effects.
    • Advances in pain pharmacogenetics can optimize therapeutic outcomes for patients on opioid therapy.